TRT and Cholesterol: The HDL/LDL Picture

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

The impact of testosterone replacement therapy (TRT) on cholesterol levels, particularly HDL and LDL, is complex and can vary based on the individual and the method of testosterone administration. While some studies show a decrease in HDL (good cholesterol) and variable effects on LDL (bad cholesterol), TRT often improves overall lipid profiles by reducing total cholesterol and triglycerides, underscoring the need for careful monitoring and individualized management.

TRT and Cholesterol: Decoding the HDL/LDL Picture

For men considering or undergoing testosterone replacement therapy (TRT), understanding its potential effects on cholesterol levels is a common concern. Cholesterol, specifically high-density lipoprotein (HDL) and low-density lipoprotein (LDL), plays a critical role in cardiovascular health. The relationship between TRT and these lipid markers is nuanced, with research presenting a complex and sometimes conflicting picture.

The General Impact on Lipid Profiles

Testosterone is known to influence lipid metabolism. In general, TRT often leads to a reduction in total cholesterol and triglycerides. This can be a beneficial effect, as elevated triglycerides are an independent risk factor for cardiovascular disease. However, the effects on HDL and LDL are more variable and depend on several factors, including the type and route of testosterone administration, as well as individual patient characteristics.

HDL Cholesterol: The "Good" Cholesterol

HDL cholesterol is often referred to as "good cholesterol" because it helps remove excess cholesterol from the arteries, transporting it back to the liver for excretion. Many studies, particularly those involving oral testosterone formulations or short-term injectable therapy, have shown that TRT can lead to a decrease in HDL cholesterol levels. For instance, some research indicates a reduction in HDL-C by 10-20% in the initial months of therapy (Saad et al., 2021). This effect is often attributed to testosterone's influence on hepatic lipase activity, an enzyme involved in HDL metabolism.

However, it's worth noting that the impact on HDL can be less pronounced or even neutral with transdermal (gels, patches) or longer-term injectable testosterone, which tend to produce more stable physiological testosterone levels. Some long-term studies have even suggested that HDL levels may stabilize or slightly increase over extended periods of TRT (Saad et al., 2021).

LDL Cholesterol: The "Bad" Cholesterol

LDL cholesterol is often termed "bad cholesterol" because high levels can contribute to the buildup of plaque in the arteries, increasing the risk of heart disease. The effect of TRT on LDL cholesterol is less consistent than its effect on HDL. Some studies have reported a decrease in LDL cholesterol, while others show no significant change or even a slight increase. For example, a systematic review might indicate a modest reduction in LDL-C, alongside total cholesterol and triglycerides (Cureus, 2025). The variability here suggests that individual responses are significant, and the overall clinical impact of these changes needs to be considered in the broader context of cardiovascular risk.

The Route of Administration Matters

The method by which testosterone is administered plays a crucial role in its effects on lipid profiles. Oral testosterone, due to its first-pass metabolism through the liver, tends to have the most significant negative impact on HDL cholesterol. Injectable and transdermal formulations generally have a more favorable or neutral effect on HDL and LDL, as they bypass initial liver metabolism and provide more stable testosterone levels.

Overall Cardiovascular Risk and Clinical Implications

Despite the potential for changes in HDL and LDL, large-scale studies and meta-analyses have generally concluded that TRT, when appropriately prescribed and monitored in hypogonadal men, does not significantly increase the overall risk of major adverse cardiovascular events (MACE). The TRAVERSE trial, for example, found TRT to be noninferior to placebo for MACE, even with some observed changes in lipid parameters. This suggests that while lipid changes occur, they may not translate into a higher overall cardiovascular risk in a well-managed patient.

Practical Takeaway

If you're on TRT, your doctor will monitor your lipid profile, including HDL and LDL cholesterol, as part of your routine bloodwork. You'll likely see some changes, with HDL potentially decreasing and LDL showing variable responses. However, it's important to remember that the overall picture of your cardiovascular health is what matters most. Your doctor will consider your complete lipid panel, along with other risk factors, to ensure that the benefits of TRT outweigh any potential risks. Don't hesitate to discuss any concerns about your cholesterol levels; proactive management, including lifestyle modifications and potentially medication, can help maintain your cardiovascular health while on TRT.